1. Qiu, X., et al., Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med, 2011. 8(2): p. 427-36.
  2. Kendirci, M., et al., Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol, 2010. 184(4): p. 1560-6.
  3. Albersen, M., et al., Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med, 2010. 7(10): p. 3331-40.
  4. Abdel Aziz, M.T., et al., Effect of mesenchymal stem cell penile transplantation on erectile signaling of aged rats. Andrologia, 2010. 42(3): p. 187-92.
  5. Huang, Y.C., et al., The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med, 2010. 7(4 Pt 1): p. 1391-400.
  6. Garcia, M.M., et al., Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med, 2010. 7(1 Pt 1): p. 89-98.
  7. Nolazco, G., et al., Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int, 2008. 101(9): p. 1156-64.
  8. Song, Y.S., et al., Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. Int J Impot Res, 2007. 19(4): p. 378-85.
  9. Rajfer, J., J. Valeriano, and R. Sinow, Early onset erectile dysfunction is usually not associated with abnormal cavernosal arterial Inflow. Int J Impot Res, 2013. 25(6): p. 217-20.
  10. Nehra, A., et al., Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol, 1996. 156(4): p. 1320-9.
  11. Bin Lim, K. and G.B. Brock, The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function. Can J Urol, 2006. 13(2): p. 3026.
  12. Karakiewicz, P., et al., Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology, 2005. 65(1): p. 131-5.
  13. Kleinman, K.P., et al., A new surrogate variable for erectile dysfunction status in the Massachusetts male aging study. J Clin Epidemiol, 2000. 53(1): p. 71-8.
  14. Foresta, C., et al., Erectile dysfunction: symptom or disease? J Endocrinol Invest, 2004. 27(1): p. 80-95.
  15. Aversa, A., et al., Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des, 2006. 12(27): p. 3467-84.
  16. Aversa, A., et al., Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. J Endocrinol Invest, 2004. 27(2): p. 192-206.
  17. Burnett, A.L., The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens (Greenwich), 2006. 8(12 Suppl 4): p. 53-62.
  18. Wespes, E., et al., EAU Guidelines on erectile dysfunction: an update. Eur Urol, 2006. 49(5): p. 806-15.
  19. Cour, F., et al., [Recommendations to general practice doctors for first line management of erectile dysfunction]. Prog Urol, 2005. 15(6): p. 1011-20.
  20. Montague, D.K., et al., Chapter 1: The management of erectile dysfunction: an AUA update. J Urol, 2005. 174(1): p. 230-9.
  21. Hatzimouratidis, K. and D. Hatzichristou, Phosphodiesterase type 5 inhibitors: the day after. European urology, 2007. 51(1): p. 75-88; discussion 89.
  22. Hatzimouratidis, K. and D.G. Hatzichristou, Phosphodiesterase type 5 inhibitors: unmet needs. Current pharmaceutical design, 2009. 15(30): p. 3476-85.
  23. Gentile, V., et al., Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Current medical research and opinion, 2004. 20(9): p. 1377-84.
  24. Morano, S., et al., Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. European urology, 2007. 52(6): p. 1768-74.
  25. Gutierrez, P., P. Hernandez, and M. Mas, Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. International journal of impotence research, 2005. 17(4): p. 354-8.
  26. Shabsigh, R., et al., Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. The Journal of urology, 2008. 179(5 Suppl): p. S97-S102.
  27. Greco, E.A., G. Spera, and A. Aversa, Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. European urology, 2006. 50(5): p. 940-7.
  28. Fraunfelder, F.W., H.D. Pomeranz, and R.A. Egan, Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol, 2006. 124(5): p. 733-4.
  29. Evans, R.W., Sildenafil can trigger cluster headaches. Headache, 2006. 46(1): p. 173-4.
  30. Schwarz, E.R. and J. Rodriguez, Sex and the heart. Int J Impot Res, 2005. 17 Suppl 1: p. S4-6.
  31. Rashid, A., The efficacy and safety of PDE5 inhibitors. Clin Cornerstone, 2005. 7(1): p. 47-56.
  32. Shinlapawittayatorn, K., S. Chattipakorn, and N. Chattipakorn, Effect of sildenafil citrate on the cardiovascular system. Braz J Med Biol Res, 2005. 38(9): p. 1303-11.
  33. Galie, N., et al., Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005. 353(20): p. 2148-57.
  34. Kulkarni, S.K. and C.S. Patil, Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol, 2004. 26(10): p. 789-99.
  35. Czp, A., Citrulline, Viagra and BiDil–bad medicine. Altern Med Rev, 2005. 10(4): p. 265-7.
  36. Chew, K.K., et al., Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. The journal of sexual medicine, 2010. 7(1 Pt 1): p. 192-202.
  37. Aversa, A., et al., Endothelial dysfunction and erectile dysfunction in the aging man. International journal of urology : official journal of the Japanese Urological Association, 2010. 17(1): p. 38-47.
  38. Rogers, J.H. and K.J. Rocha-Singh, Endovascular therapy for vasculogenic erectile dysfunction. Curr Treat Options Cardiovasc Med, 2012. 14(2): p. 193-202.
  39. Ravipati, G., et al., Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiology in review, 2007. 15(2): p. 76-86.
  40. Dussault, S., et al., Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E-deficient mice. Hypertension, 2009. 54(5): p. 1043-9.
  41. Foresta, C., et al., The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. The journal of sexual medicine, 2009. 6(2): p. 369-72.
  42. Foresta, C., et al., PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. International journal of impotence research, 2005. 17(4): p. 377-80.
  43. Foresta, C., et al., Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. European urology, 2007. 51(5): p. 1411-7; discussion 1417-9.
  44. Foresta, C., et al., Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment. Clinical endocrinology, 2009. 71(3): p. 412-6.
  45. Ferrini, M.G., et al., Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology, 2006. 68(2): p. 429-35.
  46. Kovanecz, I., et al., Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. International journal of impotence research, 2008. 20(2): p. 202-12.
  47. Ozden, E., et al., Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. Urology, 2011. 77(3): p. 761 e1-7.
  48. Padma-Nathan, H., A. McCullough, and C. Forest, Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Current urology reports, 2004. 5(6): p. 467-71.
  49. Sanna, F., et al., Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. The journal of sexual medicine, 2009. 6(10): p. 2680-9.
  50. Min, J.K., et al., Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med, 2006. 166(2): p. 201-6.
  51. Montorsi, P., et al., The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol, 2005. 96(12B): p. 19M-23M.
  52. Borgquist, R., et al., Erectile dysfunction in healthy subjects predicts reduced coronary flow velocity reserve. Int J Cardiol, 2005.
  53. Chen, S.L., et al., Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American journal of cardiology, 2004. 94(1): p. 92-5.
  54. Chen, S.L., et al., Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chinese medical journal, 2004. 117(10): p. 1443-8.
  55. Katritsis, D.G., et al., Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2005. 65(3): p. 321-9.
  56. Chen, S., et al., Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. The Journal of invasive cardiology, 2006. 18(11): p. 552-6.
  57. Katritsis, D.G., et al., Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2007. 9(3): p. 167-71.
  58. Mohyeddin-Bonab, M., et al., Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Archives of Iranian medicine, 2007. 10(4): p. 467-73.
  59. Hare, J.M., et al., A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 2009. 54(24): p. 2277-86.
  60. Guhathakurta, S., et al., Stem cell experiments and initial clinical trial of cellular cardiomyoplasty. Asian cardiovascular & thoracic annals, 2009. 17(6): p. 581-6.
  61. Lasala, G.P., et al., Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovascular revascularization medicine : including molecular interventions, 2011. 12(1): p. 29-34.
  62. Lasala, G.P., et al., Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology, 2010. 61(6): p. 551-6.
  63. Iwase, T., et al., Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovascular research, 2005. 66(3): p. 543-51.
  64. Lu, D., et al., Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes research and clinical practice, 2011.
  65. Qiu, X., et al., Combined Strategy of Mesenchymal Stem Cells Injection with VEGF Gene Therapy for the Treatment of Diabetes Associated Erectile Dysfunction. Journal of andrology, 2011.
  66. Qiu, X., et al., Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. The journal of sexual medicine, 2011. 8(2): p. 427-36.
  67. Kendirci, M., et al., Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. The Journal of urology, 2010. 184(4): p. 1560-6.
  68. Albersen, M., et al., Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. The journal of sexual medicine, 2010. 7(10): p. 3331-40.
  69. Huang, Y.C., et al., The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. The journal of sexual medicine, 2010. 7(4 Pt 1): p. 1391-400.
  70. Garcia, M.M., et al., Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. The journal of sexual medicine, 2010. 7(1 Pt 1): p. 89-98.
  71. Lin, G., et al., Potential of adipose-derived stem cells for treatment of erectile dysfunction. The journal of sexual medicine, 2009. 6 Suppl 3: p. 320-7.
  72. Nolazco, G., et al., Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU international, 2008. 101(9): p. 1156-64.
  73. Song, Y.S., et al., Magnetic resonance evaluation of human mesenchymal stem cells in corpus cavernosa of rats and rabbits. Asian journal of andrology, 2007. 9(3): p. 361-7.
  74. Song, Y.S., et al., Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. International journal of impotence research, 2007. 19(4): p. 378-85.
  75. Bivalacqua, T.J., et al., Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American journal of physiology. Heart and circulatory physiology, 2007. 292(3): p. H1278-90.
  76. Bochinski, D., et al., The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU international, 2004. 94(6): p. 904-9.
  77. Rajfer, J., A. Rosciszewski, and M. Mehringer, Prevalence of corporeal venous leakage in impotent men. J Urol, 1988. 140(1): p. 69-71.
  78. Delcour, C., et al., Investigation of the venous system in impotence of vascular origin. Urol Radiol, 1984. 6(3-4): p. 190-3.
  79. Bookstein, J.J., Cavernosal venocclusive insufficiency in male impotence: evaluation of degree and location. Radiology, 1987. 164(1): p. 175-8.
  80. Ichim, T.E., et al., Combination stem cell therapy for heart failure. International archives of medicine, 2010. 3(1): p. 5.
  81. Yu, X.Y., et al., The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Molecular and cellular biochemistry, 2009. 332(1-2): p. 25-32.
  82. Shabbir, A., et al., Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. American journal of physiology. Heart and circulatory physiology, 2009. 296(6): p. H1888-97.
  83. Chen, L., et al., Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS one, 2008. 3(4): p. e1886.
  84. Fan, W., R. Crawford, and Y. Xiao, The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization. Differentiation; research in biological diversity, 2011. 81(3): p. 181-91.
  85. Jiang, S.Y., X.T. Xie, and J.J. Zhou, [Gene profile and fibroblast growth factor 2 expression in mesenchymal stem cell from children with aplastic anemia]. Zhonghua er ke za zhi. Chinese journal of pediatrics, 2009. 47(3): p. 218-20.
  86. Ichim, T.E., et al., Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cellular immunology, 2010. 260(2): p. 75-82.
  87. Bae, K.S., et al., Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. Yonsei medical journal, 2011. 52(3): p. 401-12.
  88. Riordan, N.H., et al., Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. Journal of translational medicine, 2009. 7: p. 29.
  89. Zhong, Z., et al., Feasibility investigation of allogeneic endometrial regenerative cells. Journal of translational medicine, 2009. 7: p. 15.
  90. Bahk, J.Y., et al., Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2010. 8(2): p. 150-60.
  91. Elhanbly, S., et al., Erectile dysfunction in smokers: a penile dynamic and vascular study. Journal of andrology, 2004. 25(6): p. 991-5.
  92. You, D., et al., Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy. Circulation, 2006. 114(4): p. 328-38.
  93. Hernigou, P., et al., Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am, 2005. 87(7): p. 1430-7.
  94. Zhong, W., et al., In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma. PLoS One, 2012. 7(7): p. e40833.
  95. Miller, T.A., Diagnostic evaluation of erectile dysfunction. Am Fam Physician, 2000. 61(1): p. 95-104, 109-10.
  96. Elhanbly, S., et al., Nocturnal penile erections: the diagnostic value of tumescence and rigidity activity units. Int J Impot Res, 2009. 21(6): p. 376-81.
  97. Golijanin, D., et al., Doppler evaluation of erectile dysfunction – part 2. Int J Impot Res, 2007. 19(1): p. 43-8.
  98. Naroda, T., et al., [Clinical studies for venogenic impotence with color Doppler ultrasonography–evaluation of resistance index of the cavernous artery]. Nihon Hinyokika Gakkai Zasshi, 1996. 87(11): p. 1231-5.